FIELD: biotechnology.
SUBSTANCE: invention relates to a peptide which demonstrates action against obesity, inhibiting accumulation of fats and destroying already accumulated fats, as well as excellent antidiabetic action, effectively reducing blood sugar levels. Peptide of the present invention reduces expression of adipogenic markers PPARγ, ACC and/or aP2, increases expression of lipolytic factors pHSL, AMPK-α1, CGI-58 and/or ATGL and reduces adipocyte size and blood cholesterol levels.
EFFECT: excellent activity and stability of the peptide of the present invention can be effectively used in medicines and quasi-medicinal products.
13 cl, 24 dwg, 8 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS, APPLICATIONS AND METHODS OF TREATING METABOLIC DISORDERS AND DISEASES | 2012 |
|
RU2697762C2 |
| REGULATION OF METABOLISM USING MIR-378 | 2011 |
|
RU2585491C2 |
| COMPOSITION FOR HYPERLIPIDEMIA TREATMENT CONTAINING OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2642267C2 |
| IMMUNOGENIC HYBRID POLYPEPTIDES AGAINST OBESITY AND COMPOSITION OF ANTI-OBESITY VACCINES, CONTAINING SAID POLYPEPTIDES | 2007 |
|
RU2418005C2 |
| NEW DERIVATIVES OF OXYNTOMODULIN AND PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY | 2012 |
|
RU2612906C2 |
| PEPTIDES OF DIRECTED ACTION OF VEGFR-1/NRP-1 | 2008 |
|
RU2488592C2 |
| METHODS FOR MODULATING INTESTINAL MICROBIOTA | 2017 |
|
RU2738265C2 |
| ANTIBODY SPECIFICALLY BINDING TO GLP-1R AND FUSION PROTEIN THEREOF WITH GLP-1 | 2014 |
|
RU2681857C2 |
| CONJUGATE, CONTAINING OXYNTOMODULIN AND FRAGMENT OF IMMUNOGLOBULIN, AND USE THEREOF | 2012 |
|
RU2607365C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING A POLYPEPTIDE | 2019 |
|
RU2777095C1 |
